These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1123 related items for PubMed ID: 28408137

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
    Bai H, Li H, Li W, Gui T, Yang J, Cao D, Shen K.
    Oncotarget; 2015 Sep 22; 6(28):25520-32. PubMed ID: 26267321
    [Abstract] [Full Text] [Related]

  • 3. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M, Qi Z, Liu B, Ren Y, Li H, Yang G, Zhang Q.
    Oncotarget; 2015 Sep 22; 6(28):25281-94. PubMed ID: 26325371
    [Abstract] [Full Text] [Related]

  • 4. 4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype.
    Chang TC, Yeh CT, Adebayo BO, Lin YC, Deng L, Rao YK, Huang CC, Lee WH, Wu AT, Hsiao M, Wu CH, Wang LS, Tzeng YM.
    Toxicol Appl Pharmacol; 2015 Oct 15; 288(2):258-68. PubMed ID: 26235807
    [Abstract] [Full Text] [Related]

  • 5. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.
    Zhang X, Qin T, Zhu Z, Hong F, Xu Y, Zhang X, Xu X, Ma A.
    Am J Med Sci; 2020 Feb 15; 359(2):123-129. PubMed ID: 32039764
    [Abstract] [Full Text] [Related]

  • 6. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
    Gao Y, Shan N, Zhao C, Wang Y, Xu F, Li J, Yu X, Gao L, Yi Z.
    Int J Clin Exp Pathol; 2015 Feb 15; 8(5):4923-32. PubMed ID: 26191185
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 Feb 15; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 8. Icariin enhances the chemosensitivity of cisplatin‑resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
    Jiang S, Chang H, Deng S, Fan D.
    Int J Oncol; 2019 Jun 15; 54(6):1933-1942. PubMed ID: 31081049
    [Abstract] [Full Text] [Related]

  • 9. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 10. Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.
    Tsai JP, Lee CH, Ying TH, Lin CL, Lin CL, Hsueh JT, Hsieh YH.
    Oncotarget; 2015 Oct 06; 6(30):28851-66. PubMed ID: 26311737
    [Abstract] [Full Text] [Related]

  • 11. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
    Ding YH, Zhou ZW, Ha CF, Zhang XY, Pan ST, He ZX, Edelman JL, Wang D, Yang YX, Zhang X, Duan W, Yang T, Qiu JX, Zhou SF.
    Drug Des Devel Ther; 2015 Oct 06; 9():425-64. PubMed ID: 25624750
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J, Bai X, Feng X, Ni J, Beretov J, Graham P, Li Y.
    BMC Cancer; 2019 Jun 24; 19(1):618. PubMed ID: 31234823
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways.
    Zhang L, Wang H, Xu J, Zhu J, Ding K.
    Toxicol Lett; 2014 Aug 04; 228(3):248-59. PubMed ID: 24875536
    [Abstract] [Full Text] [Related]

  • 15. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ, Heo JH, Park JY, Jeong JY, Cho HJ, Park KS, Kim SH, Moon YW, Kim JS, An HJ.
    Gynecol Oncol; 2019 Apr 04; 153(1):135-148. PubMed ID: 30686552
    [Abstract] [Full Text] [Related]

  • 16. The fucosylated CD147 enhances the autophagy in epithelial ovarian cancer cells.
    Hu Z, Cai M, Deng L, Zhu L, Gao J, Tan M, Liu J, Lin B.
    Oncotarget; 2016 Dec 13; 7(50):82921-82932. PubMed ID: 27863372
    [Abstract] [Full Text] [Related]

  • 17. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 18. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
    Chen J, Wang Q, Zhang W, Li L.
    Zhonghua Fu Chan Ke Za Zhi; 2016 Apr 25; 51(4):285-92. PubMed ID: 27116987
    [Abstract] [Full Text] [Related]

  • 19. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J, Zhang L, Zhang X, Xing X.
    J Chemother; 2015 Apr 25; 27(6):358-64. PubMed ID: 25976336
    [Abstract] [Full Text] [Related]

  • 20. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR, Al-Romaizan M, Ahmed M, Thangavel S, Al-Dayel F, Beg S, Uddin S, Siraj AK, Al-Kuraya KS.
    Mol Med; 2015 May 26; 21(1):466-78. PubMed ID: 26023849
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.